182 related articles for article (PubMed ID: 24785146)
1. An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein.
McCready J; Wong DS; Burlison JA; Ying W; Jay DG
Cancers (Basel); 2014 Apr; 6(2):1031-46. PubMed ID: 24785146
[TBL] [Abstract][Full Text] [Related]
2. Extracellular Hsp90 Binds to and Aligns Collagen-1 to Enhance Breast Cancer Cell Invasiveness.
Singh P; Ramanathan V; Zhang Y; Georgakoudi I; Jay DG
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958410
[TBL] [Abstract][Full Text] [Related]
3. Detection and Analysis of Extracellular Hsp90 (eHsp90).
Cortes S; Baker-Williams AJ; Mollapour M; Bourboulia D
Methods Mol Biol; 2018; 1709():321-329. PubMed ID: 29177669
[TBL] [Abstract][Full Text] [Related]
4. Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo.
Stivarou T; Stellas D; Vartzi G; Thomaidou D; Patsavoudi E
Cancer Biol Ther; 2016 Aug; 17(8):799-812. PubMed ID: 27259689
[TBL] [Abstract][Full Text] [Related]
5. Extracellular Heat Shock Protein-90 (eHsp90): Everything You Need to Know.
Jay D; Luo Y; Li W
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883467
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally.
Li W; Tsen F; Sahu D; Bhatia A; Chen M; Multhoff G; Woodley DT
Int Rev Cell Mol Biol; 2013; 303():203-35. PubMed ID: 23445811
[TBL] [Abstract][Full Text] [Related]
7. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.
Hance MW; Dole K; Gopal U; Bohonowych JE; Jezierska-Drutel A; Neumann CA; Liu H; Garraway IP; Isaacs JS
J Biol Chem; 2012 Nov; 287(45):37732-44. PubMed ID: 22989880
[TBL] [Abstract][Full Text] [Related]
8. Emerging Roles of Extracellular Hsp90 in Cancer.
Wong DS; Jay DG
Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
[TBL] [Abstract][Full Text] [Related]
9. Methods to Assess the Impact of Hsp90 Chaperone Function on Extracellular Client MMP2 Activity.
Votra SD; Alsalih D; Bourboulia D
Methods Mol Biol; 2023; 2693():221-232. PubMed ID: 37540438
[TBL] [Abstract][Full Text] [Related]
10. Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Matrix Proteolysis.
Baker-Williams AJ; Hashmi F; Budzyński MA; Woodford MR; Gleicher S; Himanen SV; Makedon AM; Friedman D; Cortes S; Namek S; Stetler-Stevenson WG; Bratslavsky G; Bah A; Mollapour M; Sistonen L; Bourboulia D
Cell Rep; 2019 Aug; 28(7):1894-1906.e6. PubMed ID: 31412254
[TBL] [Abstract][Full Text] [Related]
11. The double-edged sword: conserved functions of extracellular hsp90 in wound healing and cancer.
Hance MW; Nolan KD; Isaacs JS
Cancers (Basel); 2014 May; 6(2):1065-97. PubMed ID: 24805867
[TBL] [Abstract][Full Text] [Related]
12. Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling.
Daoud A; Gopal U; Kaur J; Isaacs JS
Oncotarget; 2017 Dec; 8(63):106807-106819. PubMed ID: 29290990
[TBL] [Abstract][Full Text] [Related]
13. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion.
Gopal U; Bohonowych JE; Lema-Tome C; Liu A; Garrett-Mayer E; Wang B; Isaacs JS
PLoS One; 2011 Mar; 6(3):e17649. PubMed ID: 21408136
[TBL] [Abstract][Full Text] [Related]
14. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
[TBL] [Abstract][Full Text] [Related]
15. Targeting extracellular Hsp90: A unique frontier against cancer.
Sager RA; Khan F; Toneatto L; Votra SD; Backe SJ; Woodford MR; Mollapour M; Bourboulia D
Front Mol Biosci; 2022; 9():982593. PubMed ID: 36060252
[TBL] [Abstract][Full Text] [Related]
16. Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts stimulates the progression of gastric cancer.
Kasashima H; Yashiro M; Kinoshita H; Fukuoka T; Morisaki T; Masuda G; Sakurai K; Kubo N; Ohira M; Hirakawa K
Cancer Lett; 2014 Nov; 354(2):438-46. PubMed ID: 25128648
[TBL] [Abstract][Full Text] [Related]
17. LOXL2 Inhibitors and Breast Cancer Progression.
Ferreira S; Saraiva N; Rijo P; Fernandes AS
Antioxidants (Basel); 2021 Feb; 10(2):. PubMed ID: 33669630
[TBL] [Abstract][Full Text] [Related]
18. A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo.
Crowe LB; Hughes PF; Alcorta DA; Osada T; Smith AP; Totzke J; Loiselle DR; Lutz ID; Gargesha M; Roy D; Roques J; Darr D; Lyerly HK; Spector NL; Haystead TAJ
ACS Chem Biol; 2017 Apr; 12(4):1047-1055. PubMed ID: 28103010
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.
Chang J; Lucas MC; Leonte LE; Garcia-Montolio M; Singh LB; Findlay AD; Deodhar M; Foot JS; Jarolimek W; Timpson P; Erler JT; Cox TR
Oncotarget; 2017 Apr; 8(16):26066-26078. PubMed ID: 28199967
[TBL] [Abstract][Full Text] [Related]
20. Radiosynthesis, biological evaluation and preliminary microPET study of
Kang J; Young Lee J; Taş İ; More KN; Kim H; Park JH; Chang DJ
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3658-3664. PubMed ID: 30528977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
